MEMSCAP: Minutes of the Annual Combined General Meeting Held on June 3, 2025
GRENOBLE, France--(BUSINESS WIRE)--Regulatory News:
MEMSCAP (Euronext Paris: MEMS), leading provider of high-accuracy, high-stability pressure sensor solutions for the aerospace and medical markets using MEMS technology (Micro Electro Mechanical Systems), today announces that its annual combined general meeting was held on June 3, 2025, at 5:00 PM at the company's headquarters located in Parc Activillage des Fontaines, Bernin (38), France.
At the annual combined general meeting held on June 3, 2025, the shareholders of MEMSCAP S.A. approved, by a very large majority, all the resolutions submitted for their approval, with the exception of the 21 st resolution (Delegation of authority to increase capital for the benefit of employees), which was rejected in line with the recommendations of the board of directors.
The shareholders present, represented, or having voted remotely accounted for 2,094,499 shares, representing 27.57% of the shares with voting rights, and 2,749,924 votes, representing 33.06% of the total voting rights.
About MEMSCAP
MEMSCAP is a leading provider MEMS based pressure sensors, best-in-class in term of precision and stability (very low drift) for two market segments: aerospace and medical.
MEMSCAP also provides variable optical attenuators (VOA) for the optical communications market.
For more information, visit our website at: www.memscap.com
MEMSCAP is listed on Euronext Paris (Euronext Paris - Memscap - ISIN code: FR0010298620 - Ticker symbol: MEMS)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
27 minutes ago
- Business Wire
SOLVE Expands AI-Powered Predictive Pricing to Corporate Bonds with Launch of SOLVE Px for the Corporate Bond Market
NEW YORK--(BUSINESS WIRE)--SOLVE, the leading provider of pre-trade data and predictive pricing for fixed income securities markets, today announced the launch of SOLVE Px™ for the Corporate Bond Market, a new AI-driven pricing tool for the high-yield (HY) and investment-grade (IG) corporate bond markets. Covering over 100,000 corporate bonds with industry-leading precision, SOLVE Px provides predictive trade-level pricing that helps traders and portfolio managers act with greater confidence. SOLVE Px is designed to support fixed income professionals who need to make quick, well-informed decisions in often illiquid markets. Built on AI models trained with over 300 feature inputs, including SOLVE's proprietary quote data, the tool delivers pricing that dynamically adjusts to reflect evolving market conditions, enabling buy-side and sell-side users to uncover trade opportunities, manage risk, and refine execution strategies. 'SOLVE Px takes price discovery to another level by providing accurate pricing on securities, regardless of their liquidity,' said Eugene Grinberg, CEO of SOLVE. 'This offering provides real-time insight into the next likely trade level for both investment-grade and high-yield corporate bonds. With predictive pricing, we're helping traders and PMs combine their market judgment with data-driven support to improve outcomes and capture opportunity faster.' SOLVE Px is designed to provide real-time, size-specific pricing data at Bid, Mid, and Offer levels as well as Price, Yield and Spread for each prediction. Delivered via the SOLVE Quotes web application, FTP and FIX feeds, and soon through APIs and Excel add-in, the solution enhances transparency and pricing accuracy by integrating two core components: SOLVE Quotes™ – crowd-sourced bids and offers from market participants, providing rich real-time pricing inputs: Real-time bid, mid, and offer levels delivered across 50,000+ daily securities and 20 million+ daily quotes. AI-Generated Predictive Pricing – a fully machine learning-driven model trained on hundreds of inputs derived from reference data, trade data, and quote data. Together, these components provide a more comprehensive and actionable view of corporate bond pricing. SOLVE Px supports decision-making for traders, portfolio managers, researchers, wealth managers, and investment leaders seeking to boost execution confidence and expand investment visibility. The launch of SOLVE Px for the Corporate Bond Market builds on SOLVE's recent rollout of its Relative Value Analysis tool for municipal bonds, a capability that now also supports corporate bonds. The solution brings powerful visualization capabilities that allow traders and portfolio managers to assess how a bond's value has changed over time, providing clearer context and deeper insight into price behavior in response to market conditions. Grinberg added, 'Combining SOLVE Px with our new Relative Value Analysis tool helps corporate bond traders uncover opportunities in volatile and dynamic markets with unmatched speed and precision. Together, they provide a fuller view of the market, layering real-time predictive pricing with historical context to support smarter trading decisions.' To learn more about SOLVE Px for the Corporate Bond Market, visit SOLVE's website. About SOLVE SOLVE is the leading market data platform provider for fixed-income securities, trusted by sophisticated buy-side and sell-side firms worldwide. Founded in 2011, SOLVE leverages its AI-driven technology and deep industry expertise to offer unparalleled transparency into markets, reduce risk, and save hundreds of hours across front-office workflows. With the largest real-time datasets for Securitized Products, Municipal Bonds, Corporate Bonds, Syndicated Bank Loans, Convertible Bonds, CDS, and Private Credit, SOLVE empowers clients to transform the way they bring new securities to market, trade on secondary markets, and value highly illiquid securities. Headquartered in New York, with offices across the globe, SOLVE is the definitive source for market pricing in Fixed Income markets. For more information, visit *SOLVE Px does not constitute Investment Advice and does not seek to value any security and does not purport to meet the objectives or needs of specific individuals or accounts.
Business Wire
28 minutes ago
- Business Wire
Veradigm Launches Smart Medicine Podcast to Explore the Evolution of Healthcare
CHICAGO--(BUSINESS WIRE)-- Veradigm ® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, today launched the Smart Medicine Podcast, hosted by renowned podcaster and orthopedic surgeon, Dr. Scott Sigman. The show will provide insights and inspiration for clinicians along with other healthcare professionals, as well as payer and life science industry leaders striving to navigate the complexities of modern medicine through incremental insight. The podcast features expert guests including physicians, entrepreneurs, business leaders, and healthcare innovators – who will share their journeys, discuss challenges, and reveal the strategies that enable them to thrive. Through in-depth discussions, Smart Medicine will explore how providers are leveraging both time-tested and emerging strategies to enhance patient care, optimize business operations, and shape the future of healthcare. Future episode topics will include value-based care, medical entrepreneurship, point of care innovation, clinical and operational workflow practice management, revenue cycle management, patient and staff engagement and satisfaction, the impact of government and regulation on private practice, and the business of healthcare. 'By highlighting the real-world challenges, stakes, and rewards of these innovations, Smart Medicine will serve as a trusted guide for those navigating the intersection of medicine and business,' said Ray Joske, VP of Marketing at Veradigm. 'Each episode will follow an inspirational arc, spotlighting the obstacles overcome, the lessons learned, and the transformative impact of doing healthcare right.' Dr. Sigman is a nationally and internationally recognized leader in opioid-sparing surgery, with over 25 years of clinical experience as an orthopedic surgeon specializing in knee and shoulder procedures. Widely respected in professional education and medical device development, he has authored numerous peer-reviewed publications, and his TEDx talk on the evolution of the opioid crisis has been widely acclaimed within the industry. His podcast The Ortho Show became a go-to source for the latest in orthopedic news, growing to reach more than 8,000 listeners monthly, with more than 250 episodes. Click here to listen to new episodes of Smart Medicine. About Veradigm® Veradigm is a healthcare technology company that drives value through its unique combination of platforms, data, expertise, connectivity, and scale. The Veradigm Network features a dynamic community of solutions and partners providing advanced insights, technology, and data-driven solutions for the healthcare provider, payer, and biopharma markets. For more information about how Veradigm is fulfilling its mission of Transforming Health, Insightfully, visit or find Veradigm on LinkedIn, Facebook, Twitter, Instagram, and YouTube. © 2025 Veradigm LLC and/or its affiliates. All rights reserved. Cited marks are the property of Veradigm LLC and/or its affiliates. All other product or company names are the property of their respective holders, all rights reserved.
Business Wire
29 minutes ago
- Business Wire
Lineage Cell Therapeutics Announces Updates to the 3 rd Annual Spinal Cord Injury Investor Symposium
CARLSBAD, Calif.--(BUSINESS WIRE)-- Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or 'off the shelf', cell therapies for serious neurological and ophthalmic conditions, today announced additional presenters to the 3 rd Annual Spinal Cord Injury Investor Symposium ("3 rd SCIIS"). The 3rd SCIIS will be a fully virtual event, with interactive and on-demand sessions available starting on June 27, 2025. 'We are excited by the incredible response by presenters that have confirmed to date and believe that our third symposium will offer attendees the most comprehensive and relevant discussions related to the field of spinal cord injury we have been able to assemble to date,' stated Brian M. Culley, Lineage CEO. 'We believe collaborative problem-solving is an integral component to the goal of supporting individuals living with SCI and we are proud to bring together a diverse and broad array of clinical and preclinical companies, thought leader perspectives, and most importantly, insights from persons with lived experience. This event will be open and accessible online at no cost, and we invite you to register directly through the symposium website and to join us for the virtual event on June 27 th as we again assemble a unique group of forward-thinking leaders in SCI product development.' Current confirmed thought leaders, persons with lived experience and moderating healthcare analysts (subject to change): Armin Curt, M.D., Full Professor for Paraplegiology and Medical Director, Balgrist University Hospital, Zurich, Switzerland Richard G. Fessler, M.D., Ph.D., Professor, Department of Neurosurgery, RUSH University Medical Center James D. Guest, M.D., Ph.D., Clinical Professor, Department of Neurological Surgery, The Miami Project to Cure Paralysis, Professor, University of Miami Miller School of Medicine Steven Kirshblum, M.D., Chief Medical Officer, Kessler Foundation, Professor of Physical Medicine and Rehabilitation, Rutgers New Jersey Medical School Edelle Field-Fote, PT, Ph.D., FAPTA, FASIA, Director, Spinal Injury Research & The Hulse Spinal Injury Laboratory, Shepherd Center John (Kip) Kramer, Ph.D., Associate Professor, Department of Anesthesiology, Pharmacology, and Therapeutics, University of British Columbia Monica A. Perez, PT, Ph.D., Scientific Chair, Arms + Hands Lab, Shirley Ryan AbilityLab, Professor of Physical Medicine and Rehabilitation, Northwestern University Jeffrey C. Petruska, Ph.D., Associate Professor, University of Louisville, Department of Anatomical Sciences and Neurobiology Jerod & Hanna Nieder, Positively Paralyzed, LLC Robert Paylor, Motivational Speaker and Author , Executive Director, Portfolio Strategy & Governance, BeOne Medicines USA Barry Munro B.A., LLB., Chief Development Officer, Canadian Spinal Research Organization Jack Allen, CFA, Senior Research Analyst, Biotechnology, R.W. Baird & Co., Inc. Joseph Pantginis, Ph.D., Director of Research, Managing Director, Equity Research, H.C. Wainwright & Co., Inc. Current corporate presenters (subject to change): The 3 rd Annual Spinal Cord Injury Investor Symposium will be a fully virtual event open to all participants, with interactive and on-demand sessions available on June 27, 2025. This event will bring together both public and private companies developing new treatment options for people with spinal cord injury, alongside leaders in the spinal cord injury medical and advocacy communities. A number of important topics will be discussed, including but not limited to preclinical and clinical SCI treatment approaches and the drug development process; racial, ethnic, socioeconomic, geographic vulnerabilities within SCI care and outcomes; hearing the persons with lived experience voice and ensuring patient's perspectives, needs and priorities are captured in the drug development process; and discussions of SCI clinical endpoints and the need for new and more precise assessment tools. For more information, please visit or follow the event on X/Twitter @SCISymposium. About Spinal Cord Injuries A spinal cord injury occurs when the spinal cord is subjected to a severe crush or contusion and frequently results in severe functional impairment, including limb paralysis, aberrant pain signaling, and loss of bladder control and other body functions. There are approximately 18,000 new spinal cord injuries annually in the U.S. The cost of a lifetime of care for a severe spinal cord injury can be as high as $5 million. About Lineage Cell Therapeutics, Inc. Lineage Cell Therapeutics is a clinical-stage biotechnology company developing allogeneic, or 'off the shelf', cell therapies for serious neurological and ophthalmic conditions. Lineage's programs are based on its proprietary cell-based technology platform and associated development and manufacturing capabilities. From this platform, Lineage designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions similar or identical to cells found naturally in the human body. These cells are created by applying directed differentiation protocols to established, well-characterized, and self-renewing pluripotent cell lines. These protocols generate cells with characteristics associated with specific and desired developmental lineages. Cells derived from such lineages are transplanted into patients in an effort to replace or support cells that are absent or dysfunctional due to degenerative disease, aging, or traumatic injury, and to restore or augment the patient's functional activity. Lineage's neuroscience focused pipeline currently includes: (i) OpRegen ®, a retinal pigment epithelial cell therapy in Phase 2a development under a worldwide collaboration with Roche and Genentech, a member of the Roche Group, for the treatment of geographic atrophy secondary to age-related macular degeneration; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of spinal cord injuries; (iii) ReSonance (ANP1), an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; (iv) PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and (v) RND1, a novel hypoimmune induced pluripotent stem cell line being developed under a gene editing partnership. For more information, please visit or follow the company on X/Twitter @LineageCell. Forward-Looking Statements Lineage cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as "believe," 'aim,' 'may,' 'will,' 'estimate,' 'continue,' 'anticipate,' 'design,' 'intend,' 'expect,' 'could,' 'can,' 'plan,' 'potential,' 'predict,' 'seek,' 'should,' 'would,' 'contemplate,' 'project,' 'target,' 'tend to,' or the negative version of these words and similar expressions. Such statements include, but are not limited to, statements relating to: the potential effect of the 3 rd SCIIS. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Lineage's actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, but not limited to, those risks and uncertainties inherent in Lineage's business and other risks discussed in Lineage's filings with the Securities and Exchange Commission (SEC). Lineage's forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. Further information regarding these and other risks is included under the heading 'Risk Factors' in Lineage's periodic reports with the SEC, including Lineage's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the SEC and its other reports, which are available from the SEC's website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Lineage undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
